Literature DB >> 2095405

Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats.

T Aoyama1, H Kotaki, T Iga.   

Abstract

The plasma concentration of methylphenidate (MPD) enantiomers after i.v. and oral administration of 0.5-5 mg/kg dose of racemic MPD was compared in rats. In i.v. administration, there was no dose dependence in the pharmacokinetic parameters of both enantiomers in this dose range. In oral administration, although the elimination rate constant of both enantiomers was relatively constant, the total body clearance of both MPD enantiomers decreased remarkably with increasing dose. The relationship between oral dose and the area under the concentration-time curve (AUC) of the individual MPD enantiomers showed a non-linearity. That is, the AUC of both enantiomers increased dramatically with increasing dose more than 2 mg/kg. The recovery (MPD + the metabolite) in urine for 24 h was 16-18% in the range of the oral doses. These results suggest that the dose-dependent characteristics of the MPD enantiomers may be due to the saturation in the presystemic elimination of the drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2095405     DOI: 10.1248/bpb1978.13.647

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  15 in total

1.  Pharmacokinetics of methylphenidate following two oral formulations (immediate and sustained release) in the dog.

Authors:  M Giorgi; U Prise; G Soldani; D Neri; E Lavy
Journal:  Vet Res Commun       Date:  2010-06       Impact factor: 2.459

2.  Comparison of the VTA and LC response to methylphenidate: a concomitant behavioral and neuronal study of adolescent male rats.

Authors:  Tahseen J Karim; Cruz Reyes-Vazquez; Nachum Dafny
Journal:  J Neurophysiol       Date:  2017-06-14       Impact factor: 2.714

3.  Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder.

Authors:  Britahny M Baskin; Linda P Dwoskin; Kathleen M Kantak
Journal:  Pharmacol Biochem Behav       Date:  2015-01-31       Impact factor: 3.533

Review 4.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 5.  A review of psychostimulant-induced neuroadaptation in developing animals.

Authors:  Normand Carrey; Michael Wilkinson
Journal:  Neurosci Bull       Date:  2011-06       Impact factor: 5.203

6.  The effects of adolescent methylphenidate self-administration on responding for a conditioned reward, amphetamine-induced locomotor activity, and neuronal activation.

Authors:  Christie L Burton; José N Nobrega; Paul J Fletcher
Journal:  Psychopharmacology (Berl)       Date:  2009-12-18       Impact factor: 4.530

7.  Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine.

Authors:  Ronald Kuczenski; David S Segal
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

8.  The multifaceted effects of oral administration of methylphenidate in juvenile rats: anxiety, activity, and attention.

Authors:  Ning Zhu; Jeremy Weedon; Diana L Dow-Edwards
Journal:  Eur Neuropsychopharmacol       Date:  2010-01-18       Impact factor: 4.600

9.  A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior.

Authors:  Panayotis K Thanos; Lisa S Robison; Jessica Steier; Yu Fen Hwang; Thomas Cooper; James M Swanson; David E Komatsu; Michael Hadjiargyrou; Nora D Volkow
Journal:  Pharmacol Biochem Behav       Date:  2015-01-29       Impact factor: 3.533

10.  Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers.

Authors:  T Aoyama; H Kotaki; T Sasaki; Y Sawada; Y Honda; T Iga
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.